Amylyx Pharmaceuticals, Inc.
AMLX
Rank in Stocks
#4497
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Share Price
$27.25
Last synced: 2026-10-19
Market Cap
$3.42B
Change (1 day)
3.45%
Change (1 year)
77.29%
Country
US
Trade Amylyx Pharmaceuticals, Inc. (AMLX)
Category
Healthcare
Stock split history for Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. stock (symbol: AMLX) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 20, 2026.
One AMLX share bought prior to Oct 20, 2026 would equal to 0 AMLX shares today.
The most recent stock split occurred on Oct 20, 2026.
One AMLX share bought prior to Oct 20, 2026 would equal to 0 AMLX shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
